HUTCHMED (China) Limited discovers, develops and markets targeted immunotherapies and therapies for cancer and immune diseases globally. The company is headquartered in Central, Hong Kong.
| Revenue (TTM) | $548.51M |
| Gross Profit (TTM) | $63.87M |
| EBITDA | $-25.85M |
| Operating Margin | -13.20% |
| Return on Equity | 45.30% |
| Return on Assets | -1.62% |
| Revenue/Share (TTM) | $3.19 |
| Book Value | $7.20 |
| Price-to-Book | 1.59 |
| Price-to-Sales (TTM) | 3.48 |
| EV/Revenue | 1.307 |
| EV/EBITDA | 1.39 |
| Quarterly Earnings Growth (YoY) | -98.10% |
| Quarterly Revenue Growth (YoY) | -16.50% |
| Shares Outstanding | $171.95M |
| Float | $102.72M |
| % Insiders | 0.01% |
| % Institutions | 2.58% |
Volatility is currently expanding
First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma in China First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma in China
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, 2026 on Thursday, July 30, 2026 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT).
SEATTLE--(BUSINESS WIRE)--Syndio, the Decision Intelligence for Pay company, today announced the acquisition of Embrace.ai, an agentic AI company built to deploy AI-driven automation across business workflows. The full Embrace.ai team, led by founders and enterprise software veterans Derek Butts and Seth Halpern, will join Syndio's product and go-to-market organization. The acquisition bolsters the Syndio team with deep experience across enterprise human capital management (HCM), large-scale so.
– No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% – – Consistent and clinically meaningful improvements observed in echocardiogram parameters, biomarkers, symptoms and functional status across obstructive and nonobstructive HCM – – EDG-7500 administration continued to be generally well tolerated – – Company to host webcast today at 8:30 a.m. Eastern Time – BOULDER, Colo.
LAS VEGAS, June 15, 2026 (GLOBE NEWSWIRE) -- Connect for Partners – isolved®, a provider of human capital management (HCM) solutions that help organizations recruit, retain and elevate their workforce, proudly recognized top-performing partners during its annual isolved Connect for Partners. Now in its ninth year, Connect for Partners has grown into the premier gathering for the isolved partner community bringing together hundreds of HR and benefits providers for immersive product deep-dives, peer connection and forward-looking strategy sessions designed to sharpen competitive edge and accelerate client outcomes.
LAS VEGAS, June 15, 2026 (GLOBE NEWSWIRE) -- Connect For Partners – isolved, a provider of human capital management (HCM) solutions that help organizations recruit, retain and elevate their workforce, today announced new additions to its Strategic Marketplace — a curated ecosystem of best-in-class technology partners, each selected for the specific, meaningful value they bring to isolved clients and their employees. These additions — Corestream, Electric, OrgChart, PosterElite and Remote — extend the power of isolved People Cloud™ with trusted partner solutions built to streamline, scale and support every stage of the employee experience.
Paychex named a leading HCM provider to TIME's America's Top WorkTech Companies 2026 List List identifies the most impactful and financially strong companies that have established themselves as leaders in shaping how people and organizations work ROCHESTER, N.Y., June 15, 2026 (GLOBE NEWSWIRE) -- Paychex, Inc. (Nasdaq: PAYX), an industry-leading human capital management (HCM) company, today announced that the company has been named to the inaugural list of America's Top WorkTech Companies presented by TIME and Statista.
— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile — —The ESLIM-02 study underscores sovleplenib's potential to address critical unmet needs in a treatment landscape currently devoid of approved targeted therapies — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 12, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces results from the Phase III part of the ESLIM-02 study of sovleplenib in patients with warm antibody autoimmune hemolytic anemia (“wAIHA”) in China were presented on Thursday, June 11, 2026 during the European Hematology Association (“EHA”) Congress in Stockholm, Sweden.
HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting taking place from May 29 to June 2, 2026 in Chicago, USA.
Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study
